ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report
Revised

Case Report: Good responsiveness of metastatic sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation to immune checkpoint inhibitor after radical surgery and chemotherapy

[version 2; peer review: 2 approved]
PUBLISHED 31 Mar 2022
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Oncology gateway.

Abstract

Background: Sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation (SUCCD) in the ureter has a poor prognosis and is a rare histological variant of ureteral cancer. The majority of ureteral cancers are urothelial carcinomas.
Clinical case: We present a case of well-controlled metastatic SUCCD treated with an immune checkpoint inhibitor after radical surgery and failed adjuvant chemotherapy. The patient was a 68-year-old male with previous cure history of cT1 staged esophageal squamous cell carcinoma referred to the urology department for a right hydronephroureterosis complicating an intraureteral enhancing mass. After ureteroscopic biopsy and intraureteral urine cytology, atypical pleomorphic cell nests and chondroid tissue consistent with sarcomatoid urothelial carcinoma were observed. The patient underwent a successful radical right nephroureterectomy with bladder cuffing. The final diagnosis was a pT3N0 sarcomatoid urothelial carcinoma (heterologous component: chondrosarcoma > 95%) located at the right distal ureter and right renal calyx with infiltration of the periureteric fat and renal parenchyma of the renal capsule. On the postoperative one-month follow-up computed tomography scan, multiple enlarged lymph nodes and metastatic lung nodules were detected. The initiated three cycles of gemcitabine-carboplatin therapy was marked by disease progression; thus, second-line therapy with atezolizumab was used for treatment. After five cycles of atezolizumab, the tumors showed a partial response without any grade 3 complications.
Conclusion: The recurrent metastatic SUCCD showed good response to the immune checkpoint inhibitor after unsuccessful therapy with radical surgery and first line chemotherapy despite the unfavorable outcome of the pathology.

Keywords

urothelial carcinoma, sarcoma, chondrosarcoma, immune checkpoint inhibitor, atezolizumab

Revised Amendments from Version 1

We followed the recommended remark of editors and reviewers that a new reference was added and some sentences and phrases were deleted better to understand the case report.
There exist several papers elucidating the importance of genetic profiling in sarcomatoid urothelial carcinoma. One article from Cell Press (Cell Rep. 2019 May 7;27(6):1781-1793.e4. doi: 10.1016/j.celrep.2019.04.048.) introduced Bogdan Czerniak and his research team research about a comprehensive genomic analysis of 28 cases of SARC and 84 cases of conventional urothelial carcinoma (UC), with the TCGA cohort of 408 muscle-invasive bladder cancers serving as the reference. They found out that sarcomtoid urothelial carcinoma showing a distinct mutational landscape, with enrichment of TP53, RB1, and PIK3CA mutations which might give important implications for the development of more effective therapies such as immune check-point inhibitors.  We added this reference and their research articles whether it is possible that the genetic profiling might be an important implications for future effective therpies using immune therapy in sarcomatoid urothelial carcinoma. We added some of the sentences to show the genetic profiling research in sarcomatoid urothelial carcinoma in the manuscript.
We also added a new reference (#12) as follows in the reference section.

See the authors' detailed response to the review by Katsuhiro Ito

Introduction

Ureteral cancer is rare, with a prevalence of less than 10% of all urinary tract urothelial carcinomas. Most (>90%) urothelial carcinomas occurring in the ureter are transitional cell carcinomas, while the others (<10%) include sarcomatoid urothelial carcinoma, squamous cell carcinoma, adenocarcinoma, and small cell carcinoma1. Among the rare histology types, urothelial carcinoma with chondrosarcomatous differentiation is the most rare2. A recent review by Lu et al. showed a poor survival outcome in 25 sarcomatoid ureter cancer cases with chondrosarcomatous differentiation2. In this case study, we present a 68-year-old patient recently diagnosed with sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation of the right ureter discovered during esophageal cancer treatment. We thereby report a case of good response to the immune checkpoint inhibitor with an overall review of the histopathological characteristics of sarcomatoid ureteral cancer with some genetic background.

Case description

A 68-year-old male patient was referred to the urology department for right hydronephrosis complicating an incidental distal ureter stricture, which was found during an abdominal computed tomography (CT) scan for distal esophageal cancer. The patient was recently diagnosed with a 1.2 cm round-shaped distal esophageal squamous cell carcinoma, clinically stage T1, and was receiving a two-week 6600 cGy proton therapy in 33 fractions. The patient had a past medical history of restrictive lung disease, alcoholic liver cirrhosis (Child A), and was a heavy ex-smoker.

The CT treatment-planning scan showed right hydronephroureterosis due to distal ureteral stricture and ureter kinking. A CT urography was further performed at the urology department showing an abnormal ureteral kinking lesion with a distal intraureteral enhancing mass, just above the ureterovesical junction of the bladder (Figure 1A). Ureteral cancer was suspected given the findings in the right distal ureter: irregular wall thickening, and hydronephrosis with multiple small stones. Cystoscopy and microscopic urine analysis using the Nuclear Matrix Protein 22 test showed negative findings, except for benign hyperplasia of the prostate and a moderate trabeculated bladder without any voiding symptoms. Further, ureteroscopic biopsy with intraureteral urine cytology under general anesthesia found atypical cells, atypical pleomorphic cell nests, and chondroid tissue, consistent with sarcomatoid urothelial carcinoma (Figure 1B).

ecca0252-8b5e-4c83-a536-289a478d6503_figure1.gif

Figure 1.

(A) Preoperative CT urography and (B) ureteroscopy findings.

After the first two-week proton therapy, the patient underwent a successful right open radical nephroureterectomy from the 11th intercostal incision and pelvic Gibson incision for bladder cuffing without a positive resection margin and intratumoral positive lymph nodes. Macroscopically, the pelvocalyx was enlarged, and the cut surface revealed multiple whitish solid tumors measuring up to 2.1 × 1.7 × 1.3 cm in the pelvis and extending to the cortex. The tumor also involved the distal ureter (Figure 2A). Microscopically, the tumor had a biphasic appearance of a high-grade urothelial carcinoma and a sarcomatous component with chondrosarcomatous differentiation (Figure 2B). Immunohistochemical analysis indicated that the sarcomatous areas were positive for vimentin, and the areas of malignant urothelial cells were diffusely positive for pan-cytokeratin and p63 (Figure 2C). Based on the histological and immunohistochemical findings, a pT3N0 sarcomatoid urothelial carcinoma (heterologous component of chondrosarcoma positive for vimentin, p63, and pan-cytokeratin) located at the right distal ureter and a separate small tumor in the right renal calyx were diagnosed. The tumor in the renal calyx infiltrated the periureteric fat and renal parenchyma of the renal capsule.

ecca0252-8b5e-4c83-a536-289a478d6503_figure2.gif

Figure 2.

(A) Gross specimen of a right distal ureter mass and of a satellite renal pelvis tumor, (B) microscopic findings, and (C) immunohistochemical findings. (A) The cut surface of the resected kidney shows multiple whitish solid homogenous masses in the pelvic region extending to the renal parenchyma. The tumor in the distal ureter shows an irregular nodularity on the surface, a thickened wall, and periureteric fat invasion. (B) The tumor shows an area of urothelial carcinoma forming an epithelial component and sarcomatous area with abundant chondroid production, and the two components are fused together. (C) Immunohistochemical staining shows strong cytokeratin positivity in the urothelial carcinoma component and vimentin positivity in the cartilaginous sarcoma component.

The patient was discharged within 10 days without any complication including azotemia and resumed the two-week proton therapy for esophageal cancer. On the postoperative one-month follow-up CT scan, an increased size and necrosis of aortocaval lymph nodes and multiple metastatic lung nodules were detected. Three cycles of gemcitabine and carboplatin (gemcitabine 1000mg/m2 D1, 8, and carboplatin AUC 5 D1, every 3 weeks) chemotherapy was administered due to the decreased renal function because of an underlying chronic kidney disease. The follow-up imaging after 3 cycles (9 weeks) of the initial treatment regimen indicated disease progression; thus, a second-line systemic therapy was initiated using an immune checkpoint inhibitor, atezolizumab (1200mg, every 3 weeks). After three cycles of atezolizumab, the multiple enlarged lymph nodes and lung nodules were no longer enlarged, and after five cycles of atezolizumab the overall size of multiple metastatic lesions decreased (Figure 3), indicating a partial response to atezolizumab. The patient has undergone seven cycles of atezolizumab without any grade 3 adverse event, and will continue to be treated.

ecca0252-8b5e-4c83-a536-289a478d6503_figure3.gif

Figure 3. Comparison of metastatic tumors between baseline CT at the start of the immune check point inhibitor and follow-up CT after five cycles of the immune check point inhibitor.

Discussion

According to the 4th edition of the World Health Organization Classification of Tumors, the International Agency for Research on Cancer defined the sarcomatoid variants of urothelial carcinoma as being histologically indistinguishable from those of sarcomas with a prevalence of 0.6% of all bladder tumors3. The most common symptom of SUCCD is gross hematuria with male predominance (ratio 3:1). The aggressive pathologic feature results in mostly nodal and visceral metastases at the time of diagnosis, like in our case. Our patient had an underlying alcoholic liver cirrhosis, a chronic pulmonary disease, and a distal esophageal cancer being treated with radiation therapy. He was diagnosed with pT3NxM0 chondrosarcoma with multiple sites at the distal (pT2) and the proximal ureter (pT3). Our case was similar to a surgical case of an 81-year-old Japanese female with a multifocal, synchronous pT2 sarcomatoid ureteral cancer and pT3 renal pelvic urothelial carcinoma with multiple visceral metastases diagnosed on postoperative month 114. Our patient had no nodal enlargement or metastases at the time of preoperative workups; however, the lung metastases and multiple nodal enlargement observed on postoperative month one strongly support the speculation that micrometastases were already present at the time of diagnosis of the right hydronephroureterosis and surgery. It is also worth noting that our patient presented with multiple gross hematurias during the esophageal cancer workups, and the right atrophic kidney with cystic changes and hydronephrosis were suggestive of a long-existent tumor.

The prognosis of SUCCD is dismal (3–24 months survival time)2 because the majority of urothelial carcinoma cases with sarcomatoid differentiation are known to be high grade, with an increased risk of micrometastases at the time of diagnosis due to late diagnosis, and have challenges associated with diagnosing a rare multifocal ureteral cancer58. Therefore, surgical resection is the primary treatment choice especially for chemoradiation-resistant tumors despite diagnosis at advanced stages. However, several retrospective case series and clinical trials have proposed the use of either anti-angiogenic inhibitors or immune therapy in the current genetic era.

Immunotherapy has had enormous success in treating multiple cancer subtypes. Success has been particularly seen with immune checkpoint inhibitors, which are now approved as standard therapy in melanoma, lung cancer, and genitourinary cancers. Immunotherapy agents are increasingly demonstrating success in many cancer subtypes, and there have been preclinical suggestions that they may do the same in chondrosarcoma. The PI3K-Akt-mTOR, SRC, and Hedgehog pathways are the potential oncogenic targets for chondrosarcoma with VEGF2 inhibitors9,10. Other identified targets with next-generation sequencing are recurrent alterations in TP53, ACVR2A, COL2A1, YEATS2, and IDH11. Another research showed a distinct mutational landscape, with enrichment of TP53, RB1, and PIK3CA mutations in sarcomatoid urothelial carcinoma of bladder12. Some downregulation of homotypic adherence genes and dysregulation of the EMT network were also observed with nearly half exhibiting a heavily infiltrated immune phenotype. In addition, immune checkpoint inhibitors have been successful treatments for sarcomas. Atezolizumab, an immune checkpoint inhibitor, has been approved for second-line therapy in ureteral cancer in Korea and in our case we observed a good response. A previous 67-year-old male patient treated with four cycles of nivolumab resulted in a near-complete response in metastatic pulmonary nodules13. Immune checkpoint inhibitors have been suggested to provide tumor-specific immune responses against cancer-specific antigens such as NY-ESO-1 or LAGE-1 in sarcoma patients with dedifferentiated chondrosarcoma, as well as chondrosarcoma cell lines1315. The expected favorable outcome with the use of a single agent PD1 inhibitor with/without immunomodulatory agents in chondrosarcoma needs to be further investigated.

In conclusion, this recurrent metastatic case of carcinoma is a rare variant of multifocal synchronous ureteral cancers which responded well to atezolizumab. Our findings will help in early diagnosis, treatment planning, and better management with immune checkpoint inhibitors in case the current chemotherapy fails; thus, ensuring improved prognoses. In future, a series of case reports and studies would highlight the clinical benefit of checkpoint inhibitors with/without immunomodulatory agents in this disease clearly.

Ethical considerations and consent

Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient and the caregiver of the patient.

This retrospective study was approved by the Institutional Review Board (IRB) of the National Cancer Center (IRB No. NCC 2020- 0313-0001). This case report was proceeded in accordance with the tenets of the ethical guidelines and regulations of the World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 15 Dec 2020
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Lee HH, Kang HJ, Park WS et al. Case Report: Good responsiveness of metastatic sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation to immune checkpoint inhibitor after radical surgery and chemotherapy [version 2; peer review: 2 approved]. F1000Research 2022, 9:1458 (https://doi.org/10.12688/f1000research.27244.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 2
VERSION 2
PUBLISHED 31 Mar 2022
Revised
Views
8
Cite
Reviewer Report 31 Mar 2022
Katsuhiro Ito, Department of Urology, Kyoto University, Ishida Fushimi-ku, Kyoto, Japan 
Approved
VIEWS 8
The authors provided appropriate amendments.

"He was diagnosed with pT3NxM0 chondrosarcoma with multiple sites at the distal (pT2) and the proximal ureter (pT3)." - This sentence should be corrected because this patient was diagnosed with sarcomatoid urothelial ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Ito K. Reviewer Report For: Case Report: Good responsiveness of metastatic sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation to immune checkpoint inhibitor after radical surgery and chemotherapy [version 2; peer review: 2 approved]. F1000Research 2022, 9:1458 (https://doi.org/10.5256/f1000research.122844.r129407)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 1
VERSION 1
PUBLISHED 15 Dec 2020
Views
15
Cite
Reviewer Report 29 Nov 2021
Katsuhiro Ito, Department of Urology, Kyoto University, Ishida Fushimi-ku, Kyoto, Japan 
Approved with Reservations
VIEWS 15
In this study, the authors reported the case of sarcomatoid urothelial carcinoma with chondrosarcomatous component and the favorable response to the immune checkpoint inhibitor. Although sarcomatoid urothelial carcinoma of the ureter accounts for <10% of ureteral cancer, I think chondrosarcomatous ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Ito K. Reviewer Report For: Case Report: Good responsiveness of metastatic sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation to immune checkpoint inhibitor after radical surgery and chemotherapy [version 2; peer review: 2 approved]. F1000Research 2022, 9:1458 (https://doi.org/10.5256/f1000research.30102.r100758)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 31 Mar 2022
    Sung Han KIM, Department of Urology, Urologic Cancer Center, Urologic Cancer Center, Research institute and Hospital of National Cancer Center, Goyang, 10408, South Korea
    31 Mar 2022
    Author Response
    We thank the editors and the reviewer (Prof Katsuhiro Ito) for his thoughtful suggestions and insights. The manuscript has benefited from these insightful suggestions.

    The manuscript has been rechecked ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 31 Mar 2022
    Sung Han KIM, Department of Urology, Urologic Cancer Center, Urologic Cancer Center, Research institute and Hospital of National Cancer Center, Goyang, 10408, South Korea
    31 Mar 2022
    Author Response
    We thank the editors and the reviewer (Prof Katsuhiro Ito) for his thoughtful suggestions and insights. The manuscript has benefited from these insightful suggestions.

    The manuscript has been rechecked ... Continue reading
Views
7
Cite
Reviewer Report 18 Mar 2021
Wan Song, Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea 
Approved
VIEWS 7
In this study, they presented a case of sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation in the ureter treated with an immune checkpoint inhibitor after radical surgery and failed adjuvant chemotherapy. They showed that  immune checkpoint inhibitor might be a successful ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Song W. Reviewer Report For: Case Report: Good responsiveness of metastatic sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation to immune checkpoint inhibitor after radical surgery and chemotherapy [version 2; peer review: 2 approved]. F1000Research 2022, 9:1458 (https://doi.org/10.5256/f1000research.30102.r81387)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 15 Dec 2020
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.